NCT06857175View on ClinicalTrials.gov

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Urothelial Carcinoma
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Docetaxel or Paclitaxel

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY